Disruption of a regulatory network consisting of neutrophils and platelets fosters persisting inflammation in rheumatic diseases

Frontiers in Immunology

Volumn 7, Issue MAY, 2016, Pages

  Maugeri, Norma ^a   Rovere Querini, Patrizia ^a   Manfredi, Angelo A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

HMGB1; Inflammation; Neutrophils; Platelets; Rheumatic diseases

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ANGIOGENESIS; AUTOIMMUNITY; CELL INTERACTION; DENDRITIC CELL; DIABETIC ANGIOPATHY; EXTRACELLULAR TRAP; HUMAN; MACROPHAGE; NEUTROPHIL; PATHOGENESIS; PROTEIN PROCESSING; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOSIS; VASCULITIS;

EID: 84973526824     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00182     Document Type: Review

References (154)

1. Baldini M, Manfredi AA, Maugeri N. Targeting platelet-neutrophil interactions in giant-cell arteritis. Curr Pharm Des (2014) 20:567-74. doi:10.2174/138161282004140213144840
2. Maugeri N, Baldini M, Ramirez GA, Rovere-Querini P, Manfredi AA. Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. Thromb Res (2012) 129:267-73. doi:10.1016/j.thromres.2011.12.001
3. Maugeri N, Rovere-Querini P, Baldini M, Sabbadini MG, Manfredi AA. Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol (2009) 156:395-404. doi:10.1111/j.1365-2249.2009.03921.x
4. Ramirez GA, Maugeri N, Sabbadini MG, Rovere-Querini P, Manfredi AA. Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum. Clin Exp Immunol (2014) 175:150-66. doi:10.1111/cei.12223
5. Maugeri N, Rovere-Querini P, Baldini M, Baldissera E, Sabbadini MG, Bianchi ME, et al. Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemic sclerosis. Antioxid Redox Signal (2014) 20:1060-74. doi:10.1089/ars.2013.5298
6. Maugeri N, Rovere-Querini P, Evangelista V, Covino C, Capobianco A, Bertilaccio MT, et al. Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and {beta}2 integrin-dependent cell clearance program. Blood (2009) 113:5254-65. doi:10.1182/blood-2008-09-180794
7. Manfredi AA, Rovere-Querini P, Maugeri N. Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. Curr Opin Hematol (2010) 17:3-8. doi:10.1097/MOH.0b013e3283324f97
8. Mocsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med (2013) 210:1283-99. doi:10.1084/jem.20122220
9. Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol (2012) 3(198):773-83. doi:10.1083/jcb.201203170
10. Radic M, Marion TN. Neutrophil extracellular chromatin traps connect innate immune response to autoimmunity. Semin Immunopathol (2013) 35:465-80. doi:10.1007/s00281-013-0376-6
11. Yipp BG, Kubes P. NETosis: how vital is it? Blood (2013) 122:2784-94. doi:10.1182/blood-2013-04-457671
12. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med (2007) 13:463-9. doi:10.1038/nm1565
13. Manfredi AA, Covino C, Rovere-Querini P, Maugeri N. Instructive influences of phagocytic clearance of dying cells on neutrophil extracellular trap generation. Clin Exp Immunol (2015) 179:24-9. doi:10.1111/cei.12320
14. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol (2010) 191:677-91. doi:10.1083/jcb.201006052
15. Sreeramkumar V, Adrover JM, Ballesteros I, Cuartero MI, Rossaint J, Bilbao I, et al. Neutrophils scan for activated platelets to initiate inflammation. Science (2014) 5(346):1234-8. doi:10.1126/science.1256478
16. Dwivedi N, Radic M. Citrullination of autoantigens implicates NETosis in the induction of autoimmunity. Ann Rheum Dis (2014) 73:483-91. doi:10.1136/annrheumdis-2013-203844
17. Leshner M, Wang S, Lewis C, Zheng H, Chen XA, Santy L, et al. PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures. Front Immunol (2012) 3:307. doi:10.3389/fimmu.2012.00307
18. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe (2012) 13(12):324-33. doi:10.1016/j.chom.2012.06.011
19. Hidalgo A, Chang J, Jang JE, Peired AJ, Chiang EY, Frenette PS. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med (2009) 15:384-91. doi:10.1038/nm.1939
20. Maugeri N, Campana L, Gavina M, Covino C, De Metrio M, Panciroli C, et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost (2014) 12:2074-88. doi:10.1111/jth.12710
21. Maugeri N, Manfredi AA. Tissue factor expressed by neutrophils: another piece in the vascular inflammation puzzle. Semin Thromb Hemost (2015) 41:728-36. doi:10.1055/s-0035-1564043
22. Evangelista V, Manarini S, Dell'Elba G, Martelli N, Napoleone E, Di Santo A, et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost (2005) 94:568-77. doi:10.1160/TH05-01-0020
23. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol (2010) 30:2357-61. doi:10.1161/ATVBAHA.110.207480
24. Totani L, Piccoli A, Manarini S, Federico L, Pecce R, Martelli N, et al. Src-family kinases mediate an outside-in signal necessary for beta2 integrins to achieve full activation and sustain firm adhesion of polymorphonuclear leucocytes tethered on E-selectin. Biochem J (2006) 396:89-98. doi:10.1042/BJ20051924
25. Maugeri N, Rovere-Querini P, Slavich M, Coppi G, Doni A, Bottazzi B, et al. Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol (2011) 187:970-9. doi:10.4049/jimmunol.1100261
26. Maugeri N, Rovere-Querini P, Evangelista V, Godino C, Demetrio M, Baldini M, et al. An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. PLoS One (2012) 7:e39484. doi:10.1371/journal.pone.0039484
27. Maugeri N, Franchini S, Campana L, Baldini M, Ramirez GA, Sabbadini MG, et al. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity (2012) 45(8):584-7. doi:10.3109/08916934.2012.719946
28. Rouhiainen A, Imai S, Rauvala H, Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost (2000) 84:1087-94
29. Mobarrez F, Antoniewicz L, Bosson JA, Kuhl J, Pisetsky DS, Lundback M. The effects of smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy volunteers. PLoS One (2014) 9:e90314. doi:10.1371/journal.pone.0090314
30. Varon D, Shai E. Platelets and their microparticles as key players in pathophysiological responses. J Thromb Haemost (2015) 13(Suppl 1):S40-6. doi:10.1111/jth.12976
31. Manfredi AA, Baldini M, Camera M, Baldissera E, Brambilla M, Peretti G, et al. Anti-TNFalpha agents curb platelet activation in patients with rheumatoid arthritis. Ann Rheum Dis (2016). doi:10.1136/annrheumdis-2015-208442
32. von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 209:819-35. doi:10.1084/jem.20112322
33. Pilsczek FH, Salina D, Poon KK, Fahey C, Yipp BG, Sibley CD, et al. A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus. J Immunol (2010) 185:7413-25. doi:10.4049/jimmunol.1000675
34. Grayson PC, Kaplan MJ. At the bench: neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases. J Leukoc Biol (2015) 99:253-64. doi:10.1189/jlb.5BT0615-247R
35. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol (2011) 187:490-500. doi:10.4049/jimmunol.1100123
36. Metzler KD, Fuchs TA, Nauseef WM, Reumaux D, Roesler J, Schulze I, et al. Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. Blood (2011) 117:953-9. doi:10.1182/blood-2010-06-290171
37. Knight JS, Luo W, O'Dell AA, Yalavarthi S, Zhao W, Subramanian V, et al. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res (2014) 14(114):947-56. doi:10.1161/CIRCRESAHA.114.303312
38. Knight JS, Subramanian V, O'Dell AA, Yalavarthi S, Zhao W, Smith CK, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis (2015) 74:2199-206. doi:10.1136/annrheumdis-2014-205365
39. Farrera C, Fadeel B. Macrophage clearance of neutrophil extracellular traps is a silent process. J Immunol (2013) 1(191):2647-56. doi:10.4049/jimmunol.1300436
40. Leffler J, Martin M, Gullstrand B, Tyden H, Lood C, Truedsson L, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol (2012) 188:3522-31. doi:10.4049/jimmunol.1102404
41. Chrysanthopoulou A, Mitroulis I, Apostolidou E, Arelaki S, Mikroulis D, Konstantinidis T, et al. Neutrophil extracellular traps promote differentiation and function of fibroblasts. J Pathol (2014) 233:294-307. doi:10.1002/path.4359
42. de Souza AW, Abdulahad WH, Sosicka P, Bijzet J, Limburg PC, Stegeman CA, et al. Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis? Clin Exp Immunol (2014) 178:270-8. doi:10.1111/cei.12422
43. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol (2012) 15(189):2689-95. doi:10.4049/jimmunol.1201719
44. Neeli I, Khan SN, Radic M. Histone deimination as a response to inflammatory stimuli in neutrophils. J Immunol (2008) 180:1895-902. doi:10.4049/jimmunol.180.3.1895
45. Neeli I, Radic M. Knotting the NETs: analyzing histone modifications in neutrophil extracellular traps. Arthritis Res Ther (2012) 14:115. doi:10.1186/ar3773
46. Wang H, Wang C, Zhao MH, Chen M. Neutrophil extracellular traps can activate alternative complement pathways. Clin Exp Immunol (2015) 181:518-27. doi:10.1111/cei.12654
47. Pinegin B, Vorobjeva N, Pinegin V. Neutrophil extracellular traps and their role in the development of chronic inflammation and autoimmunity. Autoimmun Rev (2015) 14:633-40. doi:10.1016/j.autrev.2015.03.002
48. Apostolidou E, Skendros P, Kambas K, Mitroulis I, Konstantinidis T, Chrysanthopoulou A, et al. Neutrophil extracellular traps regulate IL-1beta-mediated inflammation in familial Mediterranean fever. Ann Rheum Dis (2016) 75:269-77. doi:10.1136/annrheumdis-2014-205958
49. Kambas K, Chrysanthopoulou A, Vassilopoulos D, Apostolidou E, Skendros P, Girod A, et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis (2014) 73:1854-63. doi:10.1136/annrheumdis-2013-203430
50. Knight JS, Zhao W, Luo W, Subramanian V, O'Dell AA, Yalavarthi S, et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest (2013) 123:2981-93. doi:10.1172/JCI67390
51. Bianchi ME, Manfredi AA. How macrophages ring the inflammation alarm. Proc Natl Acad Sci U S A (2014) 25(111):2866-7. doi:10.1073/pnas.1324285111
52. Lu B, Antoine DJ, Kwan K, Lundback P, Wahamaa H, Schierbeck H, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A (2014) 111:3068-73. doi:10.1073/pnas.1316925111
53. Venereau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front Immunol (2015) 6:422. doi:10.3389/fimmu.2015.00422
54. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 190:881-92. doi:10.1083/jcb.200911078
55. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev (2007) 220:35-46. doi:10.1111/j.1600-065X.2007.00574.x
56. Vogel S, Bodenstein R, Chen Q, Feil S, Feil R, Rheinlaender J, et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest (2015) 125:4638-54. doi:10.1172/JCI81660
57. Yang X, Wang H, Zhang M, Liu J, Lv B, Chen F. HMGB1: a novel protein that induced platelets active and aggregation via toll-like receptor-4, NF-kappaB and cGMP dependent mechanisms. Diagn Pathol (2015) 10:134. doi:10.1186/s13000-015-0348-3
58. Castiglioni A, Canti V, Rovere-Querini P, Manfredi AA. High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res (2011) 343:189-99. doi:10.1007/s00441-010-1033-1
59. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 27(209):1519-28. doi:10.1084/jem.20120189
60. Vezzoli M, Castellani P, Campana L, Corna G, Bosurgi L, Manfredi AA, et al. Redox remodeling: a candidate regulator of HMGB1 function in injured skeletal muscle. Ann N Y Acad Sci (2010) 1209:83-90. doi:10.1111/j.1749-6632.2010.05748.x
61. Vezzoli M, Castellani P, Corna G, Castiglioni A, Bosurgi L, Monno A, et al. HMGB1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal (2011) 15(8):2161-74. doi:10.1089/ars.2010.3341
62. Hreggvidsdottir HS, Lundberg AM, Aveberger AC, Klevenvall L, Andersson U, Harris HE. High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol Med (2012) 18:224-30. doi:10.2119/molmed.2011.00327
63. Wahamaa H, Schierbeck H, Hreggvidsdottir HS, Palmblad K, Aveberger AC, Andersson U, et al. High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res Ther (2011) 13:R136. doi:10.1186/ar3450
64. Campana L, Bosurgi L, Bianchi ME, Manfredi AA, Rovere-Querini P. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol (2009) 86:609-15. doi:10.1189/jlb.0908576
65. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 12(209):551-63. doi:10.1084/jem.20111739
66. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta (2010) 1799:141-8. doi:10.1016/j.bbagrm.2009.11.003
67. Grayson PC, Maksimowicz-McKinnon K, Clark TM, Tomasson G, Cuthbertson D, Carette S, et al. Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis (2012) 71:1329-34. doi:10.1136/annrheumdis-2011-200795
68. Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol (2012) 32:259-65. doi:10.1097/WNO.0b013e318268aa9b
69. Foroozan R, Danesh-Meyer H, Savino PJ, Gamble G, Mekari-Sabbagh ON, Sergott RC. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology (2002) 109:1267-71. doi:10.1016/S0161-6420(02)01076-X
70. Kale N, Eggenberger E. Diagnosis and management of giant cell arteritis: a review. Curr Opin Ophthalmol (2010) 21:417-22. doi:10.1097/ICU.0b013e32833eae8b
71. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum (2002) 46:457-66. doi:10.1002/art.10071
72. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum (2004) 50:1332-7. doi:10.1002/art.20171
73. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum (2006) 54:3306-9. doi:10.1002/art.22141
74. Mollan SP, Sharrack N, Burdon MA, Denniston AK. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev (2014) 8:CD010453. doi:10.1002/14651858.CD010453.pub2
75. Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford) (2009) 48:258-61. doi:10.1093/rheumatology/ken480
76. Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) (2005) 84:269-76. doi:10.1097/01.md.0000180042.42156.d1
77. Maugeri N, Baldini M, Rovere-Querini P, Maseri A, Sabbadini MG, Manfredi AA. Leukocyte and platelet activation in patients with giant cell arteritis and polymyalgia rheumatica: a clue to thromboembolic risks? Autoimmunity (2009) 42:386-8. doi:10.1080/08916930902832629
78. Di Comite G, Previtali P, Rossi CM, Dell'Antonio G, Rovere-Querini P, Praderio L, et al. High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment. Ann Rheum Dis (2009) 68:293-5. doi:10.1136/ard.2007.086587
79. Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, Prieto-Gonzalez S, et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum (2012) 64:854-65. doi:10.1002/art.33411
80. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol (2008) 20:538-44. doi:10.1016/j.coi.2008.05.004
81. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 13:832-42. doi:10.1038/ni.2376
82. Dumitriu IE, Baruah P, Bianchi ME, Manfredi AA, Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol (2005) 35:2184-90. doi:10.1002/eji.200526066
83. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 174:7506-15. doi:10.4049/jimmunol.174.12.7506
84. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol (2007) 81:84-91. doi:10.1189/jlb.0306171
85. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 5:825-30. doi:10.1038/sj.embor.7400205
86. Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, Doglioni C, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med (2011) 4(155):425-33. doi:10.7326/0003-4819-155-7-201110040-00005
87. Tombetti E, Di Chio MC, Sartorelli S, Papa M, Salerno A, Bottazzi B, et al. Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. Arthritis Res Ther (2014) 16:479. doi:10.1186/s13075-014-0479-z
88. de Souza AW, van der Geest KS, Brouwer E, Pinheiro FA, Oliveira AC, Sato EI, et al. High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins. Arthritis Res Ther (2015) 17:158. doi:10.1186/s13075-015-0672-8
89. de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev (2012) 11:909-17. doi:10.1016/j.autrev.2012.03.007
90. Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, et al. High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med (2011) 17:29-35. doi:10.2119/molmed.2010.00132
91. Wang C, de Souza AW, Westra J, Bijl M, Chen M, Zhao MH, et al. Emerging role of high mobility group box 1 in ANCA-associated vasculitis. Autoimmun Rev (2015) 14:1057-65. doi:10.1016/j.autrev.2015.07.010
92. Wang C, Gou SJ, Chang DY, Yu F, Zhao MH, Chen M. Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Care Res (2013) 65:1828-34. doi:10.1002/acr.22187
93. Wibisono D, Csernok E, Lamprecht P, Holle JU, Gross WL, Moosig F. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis (2010) 69:1888-9. doi:10.1136/ard.2009.119172
94. Henes FO, Chen Y, Bley TA, Fabel M, Both M, Herrmann K, et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis (2011) 70:1926-9. doi:10.1136/ard.2010.146456
95. Ma TT, Wang H, Wang C, Chang DY, Zhao MH, Chen M. Urinary levels of high mobility group box-1 are associated with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. PLoS One (2015) 10:e0123586. doi:10.1371/journal.pone.0123586
96. de Souza A, Westra J, Bijzet J, Limburg PC, Stegeman CA, Bijl M, et al. Is serum HMGB1 a biomarker in ANCA-associated vasculitis? Arthritis Res Ther (2013) 15:R104. doi:10.1186/ar4284
97. Wang C, Wang H, Chang DY, Hao J, Zhao MH, Chen M. High mobility group box 1 contributes to anti-neutrophil cytoplasmic antibody-induced neutrophils activation through receptor for advanced glycation end products (RAGE) and toll-like receptor 4. Arthritis Res Ther (2015) 17:64. doi:10.1186/s13075-015-0587-4
98. Halbwachs L, Lesavre P. Endothelium-neutrophil interactions in ANCA-associated diseases. J Am Soc Nephrol (2012) 23:1449-61. doi:10.1681/ASN.2012020119
99. Ma YH, Ma TT, Wang C, Wang H, Chang DY, Chen M, et al. High-mobility group box 1 potentiates antineutrophil cytoplasmic antibody-inducing neutrophil extracellular traps formation. Arthritis Res Ther (2016) 18:2. doi:10.1186/s13075-015-0903-z
100. Eguchi T, Nomura Y, Hashiguchi T, Masuda K, Arata M, Hazeki D, et al. An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome. Pediatr Infect Dis J (2009) 28:339-41. doi:10.1097/INF.0b013e31818ffe60
101. Hoshina T, Kusuhara K, Ikeda K, Mizuno Y, Saito M, Hara T. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease. Scand J Rheumatol (2008) 37:445-9. doi:10.1080/03009740802144143
102. Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T, Muroi E, et al. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol (2009) 29:180-9. doi:10.1007/s10875-008-9252-x
103. Nin JW, Ferreira I, Schalkwijk CG, Jorsal A, Prins MH, Parving HH, et al. Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study. Diabetologia (2012) 55:2489-93. doi:10.1007/s00125-012-2622-1
104. Schaper NC, Havekes B. Diabetes: impaired damage control. Diabetologia (2012) 55:18-20. doi:10.1007/s00125-011-2368-1
105. DeVerse JS, Bailey KA, Jackson KN, Passerini AG. Shear stress modulates RAGE-mediated inflammation in a model of diabetes-induced metabolic stress. Am J Physiol Heart Circ Physiol (2012) 15(302):H2498-508. doi:10.1152/ajpheart.00869.2011
106. Kanellakis P, Agrotis A, Kyaw TS, Koulis C, Ahrens I, Mori S, et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol (2011) 31:313-9. doi:10.1161/ATVBAHA.110.218669
107. Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis (2009) 205:544-8. doi:10.1016/j.atherosclerosis.2008.12.016
108. Han J, Zhong J, Wei W, Wang Y, Huang Y, Yang P, et al. Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes (2008) 57:2118-27. doi:10.2337/db07-1499
109. Li M, Song L, Gao X, Chang W, Qin X. Toll-like receptor 4 on islet beta cells senses expression changes in high-mobility group box 1 and contributes to the initiation of type 1 diabetes. Exp Mol Med (2012) 30(44):260-7. doi:10.3858/emm.2012.44.4.021
110. Kruger B, Yin N, Zhang N, Yadav A, Coward W, Lal G, et al. Islet-expressed TLR2 and TLR4 sense injury and mediate early graft failure after transplantation. Eur J Immunol (2010) 40:2914-24. doi:10.1002/eji.201040601
111. Matsuoka N, Itoh T, Watarai H, Sekine-Kondo E, Nagata N, Okamoto K, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest (2010) 120:735-43. doi:10.1172/JCI41360
112. Nicolosi PA, Tombetti E, Maugeri N, Rovere-Querini P, Brunelli S, Manfredi AA. Vascular remodelling and mesenchymal transition in systemic sclerosis. Stem Cells Int (2016) 2016:4636859. doi:10.1155/2016/4636859
113. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 24(117):3216-26. doi:10.1161/CIRCULATIONAHA.108.769331
114. Ding HS, Yang J, Gong FL, Yang J, Ding JW, Li S, et al. High mobility group [corrected] box 1 mediates neutrophil recruitment in myocardial ischemia-reperfusion injury through toll like receptor 4-related pathway. Gene (2012) 509:149-53. doi:10.1016/j.gene.2012.07.072
115. Evankovich J, Cho SW, Zhang R, Cardinal J, Dhupar R, Zhang L, et al. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem (2010) 17(285):39888-97. doi:10.1074/jbc.M110.128348
116. Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, Liu S, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 293:R1538-44. doi:10.1152/ajpregu.00272.2007
117. Rabadi MM, Ghaly T, Goligorksy MS, Ratliff BB. HMGB1 in renal ischemic injury. Am J Physiol Renal Physiol (2012) 15(303):F873-85. doi:10.1152/ajprenal.00092.2012
118. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, Griffioen AW. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene (2013) 32:363-74. doi:10.1038/onc.2012.49
119. Csernok E, Moosig F, Gross WL. Pathways to ANCA production: from differentiation of dendritic cells by proteinase 3 to B lymphocyte maturation in Wegener's granuloma. Clin Rev Allergy Immunol (2008) 34:300-6. doi:10.1007/s12016-007-8056-8
120. Kallenberg CG. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun (2008) 30:29-36. doi:10.1016/j.jaut.2007.11.005
121. Rimbert M, Hamidou M, Braudeau C, Puechal X, Teixeira L, Caillon H, et al. Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One (2011) 6:e18734. doi:10.1371/journal.pone.0018734
122. Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation (2008) 16(118):1276-84. doi:10.1161/CIRCULATIONAHA.108.789172
123. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev (2011) 11:61-7. doi:10.1016/j.autrev.2011.08.001
124. Biscetti F, Straface G, De Cristofaro R, Lancellotti S, Rizzo P, Arena V, et al. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes (2010) 59:1496-505. doi:10.2337/db09-1507
125. Lolmede K, Campana L, Vezzoli M, Bosurgi L, Tonlorenzi R, Clementi E, et al. Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1-and MMP-9-dependent pathways. J Leukoc Biol (2009) 85:779-87. doi:10.1189/jlb.0908579
126. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) (2005) 83:876-86. doi:10.1007/s00109-005-0688-7
127. Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Guillevin L, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis (2009) 68:564-7. doi:10.1136/ard.2008.099051
128. Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis-incidence and risk factors. Rheumatology (Oxford) (2008) 47:530-4. doi:10.1093/rheumatology/ken035
129. McCarthy LJ, Danielson C, Weidner J, Miraglia C. Chronic severe thrombotic thrombocytopenic purpura (TTP). Ther Apher (1999) 3:348-9
130. Tomasson G, Lavalley M, Tanriverdi K, Finkielman JD, Davis JC Jr, Hoffman GS, et al. Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol (2011) 38:1048-54. doi:10.3899/jrheum.100735
131. Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood (2011) 118:6743-51. doi:10.1182/blood-2011-07-343566
132. Gupta AK, Joshi MB, Philippova M, Erne P, Hasler P, Hahn S, et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Lett (2010) 584:3193-7. doi:10.1016/j.febslet.2010.06.006
133. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol (2012) 32:1777-83. doi:10.1161/ATVBAHA.111.242859
134. Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One (2012) 7:e32366. doi:10.1371/journal.pone.0032366
135. Rauvala H, Rouhiainen A. Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim Biophys Acta (2010) 1799:164-70. doi:10.1016/j.bbagrm.2009.11.012
136. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood (2003) 101:2652-60. doi:10.1182/blood-2002-05-1300
137. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med (2003) 254:375-85. doi:10.1046/j.1365-2796.2003.01204.x
138. Bianchi ME, Manfredi AA. Immunology. Dangers in and out. Science (2009) 27(323):1683-4. doi:10.1126/science.1172794
139. Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (2009) 27(323):1722-5. doi:10.1126/science.1168988
140. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol (2012) 34:107-25. doi:10.1007/s00281-011-0282-8
141. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest (2005) 115:1267-74. doi:10.1172/JCI22782
142. Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H, et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol (2008) 28:1825-30. doi:10.1161/ATVBAHA.107.150631
143. Esmon C. Do-all receptor takes on coagulation, inflammation. Nat Med (2005) 11:475-7. doi:10.1038/nm0505-475
144. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood (1989) 73:159-65
145. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost (2006) 32(Suppl 1):49-60. doi:10.1055/s-2006-939554
146. Menashi S, Tribout B, Dosquet C, Le Toumelin P, Piette JC, Wechsler B, et al. Strong association between plasma thrombomodulin and pathergy test in Behcet disease. Ann Rheum Dis (2008) 67:892-3. doi:10.1136/ard.2007.075143
147. de Leeuw K, Bijzet J, van der Graaf AM, Stegeman CA, Smit AJ, Kallenberg CG, et al. Patients with Wegener's granulomatosis: a long-term follow-up study. Clin Exp Rheumatol (2010) 28:18-23
148. Monach PA, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, et al. Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2011) 63:3988-97. doi:10.1002/art.30615
149. Zycinska K, Wardyn KA, Zielonka TM, Krupa R, Lukas W. Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis. Eur J Med Res (2009) 14(Suppl 4):268-70. doi:10.1186/2047-783X-14-S4-268
150. Huston JM, Gallowitsch-Puerta M, Ochani M, Ochani K, Yuan R, Rosas-Ballina M, et al. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med (2007) 35:2762-8. doi:10.1097/01.CCM.0000288102.15975.BA
151. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med (2004) 10:1216-21. doi:10.1038/nm1124
152. Li F, Chen Z, Pan Q, Fu S, Lin F, Ren H, et al. The protective effect of PNU-282987, a selective alpha7 nicotinic acetylcholine receptor agonist, on the hepatic ischemia-reperfusion injury is associated with the inhibition of high-mobility group box 1 protein expression and nuclear factor kappaB activation in mice. Shock (2013) 39:197-203. doi:10.1097/SHK.0b013e31827aa1f6
153. Xiong J, Yuan YJ, Xue FS, Wang Q, Cheng Y, Li RP, et al. Postconditioning with alpha7nAChR agonist attenuates systemic inflammatory response to myocardial ischemia-reperfusion injury in rats. Inflammation (2012) 35:1357-64. doi:10.1007/s10753-012-9449-2
154. Bonaz B, Sinniger V, Pellissier S. Anti-inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. J Physiol (2016). doi:10.1113/JP271539